

Gabriele Bergers

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/8878248/publications.pdf](https://exaly.com/author-pdf/8878248/publications.pdf)

Version: 2025-02-01

53

PR articles

21,528

PR citations

49965

41

PR h-index

144667

52

g-index

60

documents

25642

doc citations

51094

44

h-index

30221

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Targeting the tumour vasculature: from vessel destruction to promotion. <i>Nature Reviews Cancer</i> , 2024, 24, 655-675.	61.8	99
2	High endothelial venules in cancer: Regulation, function, and therapeutic implication. <i>Cancer Cell</i> , 2023, 41, 527-545.	38.5	82
3	Multiomics and spatial mapping characterizes human CD8 ⁺ T cell states in cancer. <i>Science Translational Medicine</i> , 2023, 15, .	12.7	67
4	LGL1 binds to Integrin β 1 and inhibits downstream signaling to promote epithelial branching in the mammary gland. <i>Cell Reports</i> , 2022, 38, 110375.	6.4	13
5	Lipid droplet degradation by autophagy connects mitochondria metabolism to Prox1-driven expression of lymphatic genes and lymphangiogenesis. <i>Nature Communications</i> , 2022, 13, .	13.9	46
6	Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. <i>Cancer Cell</i> , 2022, 40, 1600-1618.e10.	38.5	135
7	The metabolism of cancer cells during metastasis. <i>Nature Reviews Cancer</i> , 2021, 21, 162-180.	61.8	816
8	High Endothelial Venules: A Vascular Perspective on Tertiary Lymphoid Structures in Cancer. <i>Frontiers in Immunology</i> , 2021, 12, .	5.1	79
9	Peptide-guided nanoparticles for glioblastoma targeting. <i>Journal of Controlled Release</i> , 2019, 308, 109-118.	11.1	92
10	Tumors vs. Chronic Wounds: An Immune Cell's Perspective. <i>Frontiers in Immunology</i> , 2019, 10, .	5.1	68
11	Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis. <i>Annual Review of Physiology</i> , 2019, 81, 535-560.	17.2	59
12	Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. <i>Journal of Pathology</i> , 2018, 245, 209-221.	5.0	104
13	A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma. <i>Nature Cell Biology</i> , 2018, 20, 1203-1214.	16.9	130
14	Consensus guidelines for the use and interpretation of angiogenesis assays. <i>Angiogenesis</i> , 2018, 21, 425-532.	7.9	544
15	The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 107-116.	14.1	79
16	Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. <i>Science Translational Medicine</i> , 2017, 9, .	12.7	712
17	Cross-activating c-Met/ β 1 integrin complex drives metastasis and invasive resistance in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, .	7.6	81
18	Therapeutic induction of high endothelial venules (HEVs) to enhance T-cell infiltration in tumors. <i>Oncotarget</i> , 2017, 8, 99207-99208.	1.7	10

#	ARTICLE	IF	PR CITATIONS
19	Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 21-29.	1.6	7
20	Glioblastoma: Defining Tumor Niches. Trends in Cancer, 2015, 1, 252-265.	10.6	436
21	Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy. Cell Reports, 2015, 11, 577-591.	6.4	155
22	Intertwined regulation of angiogenesis and immunity by myeloid cells. Trends in Immunology, 2015, 36, 240-249.	10.6	146
23	¹ H-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR in Biomedicine, 2014, 27, 1361-1370.	2.4	29
24	Novel Target for Peptide-Based Imaging and Treatment of Brain Tumors. Molecular Cancer Therapeutics, 2014, 13, 996-1007.	1.8	61
25	Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncology, 2013, 2, 49-65.	2.4	127
26	Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance. Clinical Cancer Research, 2013, 19, 1773-1783.	6.9	193
27	VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex. Cancer Cell, 2012, 22, 21-35.	38.5	536
28	Asymmetry-Defective Oligodendrocyte Progenitors Are Glioma Precursors. Cancer Cell, 2011, 20, 328-340.	38.5	214
29	Tumor microenvironment and progression. Journal of Surgical Oncology, 2011, 103, 468-474.	1.6	162
30	Non-Stem Cell Origin for Oligodendroglioma. Cancer Cell, 2010, 18, 669-682.	38.5	221
31	Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis. Cancer Cell, 2009, 15, 220-231.	38.5	2,237
32	Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer, 2008, 8, 592-603.	61.8	2,762
33	miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Medicine, 2008, 6, .	7.5	861
34	HIF1 α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion. Cancer Cell, 2008, 13, 206-220.	38.5	1,102
35	Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro-Oncology, 2008, 10, 254-264.	1.1	108
36	Chapter 3 Bone Marrow-Derived Vascular Progenitors and Proangiogenic Monocytes in Tumors. Methods in Enzymology, 2008, , 53-82.	2.1	3

#	ARTICLE	IF	PR CITATIONS
37	Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting. PLoS Medicine, 2008, 5, e19.	8.5	409
38	HIF1 α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis. FASEB Journal, 2008, 22, .	0.7	0
39	Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. Cancer and Metastasis Reviews, 2006, 25, 243-252.	7.2	27
40	The bone marrow constitutes a reservoir of pericyte progenitors. Journal of Leukocyte Biology, 2006, 80, 677-681.	3.0	120
41	Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood, 2005, 105, 1094-1101.	4.2	198
42	PDGFR β ⁺ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nature Cell Biology, 2005, 7, 870-879.	16.9	541
43	Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell, 2005, 8, 299-309.	38.5	1,538
44	The role of pericytes in blood-vessel formation and maintenance. Neuro-Oncology, 2005, 7, 452-464.	1.1	1,412
45	The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell, 2003, 4, 133-146.	38.5	393
46	Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 2003, 4, 393-403.	38.5	241
47	Tumorigenesis and the angiogenic switch. Nature Reviews Cancer, 2003, 3, 401-410.	61.8	3,237
48	Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Journal of Clinical Investigation, 2003, 111, 1287-1295.	10.7	563
49	Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Journal of Clinical Investigation, 2003, 111, 1287-1295.	10.7	1,130
50	Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology, 2000, 2, 737-744.	16.9	2,607
51	Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects. Expert Opinion on Therapeutic Targets, 2000, 4, 609-633.	0.8	68
52	Extrinsic regulators of epithelial tumor progression: metalloproteinases. Current Opinion in Genetics and Development, 2000, 10, 120-127.	3.2	141
53	MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes. Cell, 1998, 93, 411-422.	34.1	1,681